respiratori
infect
common
contribut
significantli
morbid
mortal
also
costli
one
lead
reason
health
care
visit
infect
respiratori
pathogen
often
result
symptom
overlap
mani
caus
agent
definit
diagnosi
requir
laboratori
test
therefor
approach
syndrom
test
wide
adopt
test
multipl
agent
upper
respiratori
infect
time
singl
test
panelbas
approach
simplifi
order
laboratori
workflow
improv
sensit
time
result
compar
older
convent
test
method
clinic
perspect
use
syndrom
diagnost
facilit
better
antimicrobi
stewardship
allow
antimicrobi
antivir
therapi
given
time
appropri
manner
misus
antibiot
case
viral
respiratori
infect
common
problem
rapid
result
detect
viral
pathogen
may
prevent
unnecessari
use
antibiot
rapid
diagnosi
respiratori
infect
also
shorten
time
emerg
room
decreas
length
stay
prevent
hospit
allow
improv
patient
cohort
prevent
nosocomi
infect
first
multiplex
respiratori
panel
clear
fda
follow
number
syndrom
assay
panel
vari
number
analyt
detect
time
result
design
simpl
use
requir
littl
handson
time
current
commerci
multiplex
assay
greater
analyt
includ
viral
pathogen
influenza
b
respiratori
syncyti
viru
human
metapneumoviru
adenoviru
parainfluenza
viru
rhinovirusenteroviru
smaller
number
panel
includ
bacteri
pathogen
chlamydophila
pneumonia
mycoplasma
pneumonia
bordetella
speci
studi
data
present
multicent
clinic
evalu
new
multiplex
respiratori
panel
qiastatdx
respiratori
panel
qiastatdx
rp
qiastatdx
rp
multiplex
realtim
pcr
test
intend
use
qiastatdx
system
simultan
qualit
detect
identif
multipl
respiratori
viral
bacteri
nucleic
acid
nasopharyng
swab
np
obtain
individu
suspect
respiratori
tract
infect
qiastatdx
rp
cartridg
run
analyz
consist
least
one
analyt
modul
individu
cartridg
load
one
oper
modul
touchscreen
integr
softwar
analyt
modul
connect
one
oper
modul
fig
follow
pathogen
type
subtyp
identifi
adenoviru
coronavirus
human
metapneumoviru
b
influenza
influenza
influenza
influenza
influenza
b
parainfluenza
virus
rhinovirusenteroviru
respiratori
syncyti
viru
b
bordetella
pertussi
chlamydophila
pneumonia
mycoplasma
pneumonia
test
perform
residu
np
collect
transport
media
prospect
retrospect
arm
studi
includ
analyt
perform
calcul
base
comparison
fdaclearedapprov
test
studi
conduct
six
geograph
distinct
site
unit
state
europ
nationwid
children
hospit
columbu
oh
hennepin
counti
medic
center
minneapoli
mn
indiana
univers
school
medicin
indianapoli
laboratori
allianc
central
new
york
liverpool
ny
tricor
refer
laboratori
albuquerqu
nm
univers
copenhagen
hvidovr
denmark
specimen
prospect
enrol
period
approxim
month
decemb
april
test
either
fresh
frozen
specimen
meet
follow
inclus
criterion
select
specimen
np
collect
transport
medium
standardofcar
soc
test
transport
media
use
studi
follow
univers
transport
medium
copan
diagnost
brescia
itali
ca
usa
microtest
thermo
fisher
scientif
usa
bd
univers
viral
transport
becton
dickinson
nj
usa
univers
transport
medium
healthlink
inc
fl
usa
univers
transport
medium
diagnost
hybrid
oh
usa
vcm
medium
quest
diagnost
nj
usa
unitranzrt
univers
transport
medium
puritan
diagnost
usa
specimen
adequ
residu
volum
ml
us
site
ml
hvidovr
hospit
held
room
temperatur
less
equal
h
less
equal
day
frozen
day
enrol
waiver
inform
consent
requir
obtain
institut
review
board
irb
studi
site
use
residu
deidentifi
np
specimen
preselect
frozen
archiv
specimen
enrol
base
identif
specif
posit
target
use
soc
test
studi
site
specimen
thaw
test
studi
site
blind
fashion
qiastatdx
rp
compar
assay
biofir
filmarray
respiratori
panel
version
compar
assay
confirm
preselect
target
posit
specimen
exclud
data
analysi
target
data
collect
prospect
retrospect
specimen
inform
includ
hospit
statu
time
specimen
collect
date
specimen
collect
subject
sex
subject
age
time
collect
panel
includ
test
detect
adenoviru
coronaviru
cov
cov
cov
human
metapneumoviru
b
hmpv
influenza
flu
flu
flu
flu
influenza
b
flu
b
parainfluenza
viru
piv
piv
piv
piv
human
rhinovirusenteroviru
rvev
respiratori
syncyti
viru
b
rsv
bordetella
pertussi
chlamydophila
pneumonia
mycoplasma
pneumonia
approxim
specimen
test
accord
manufactur
instruct
qiastatdx
respiratori
panel
cartridg
platform
consist
autom
nucleic
acid
extract
revers
transcript
pcr
fluoresc
detect
result
analysi
approxim
min
per
run
ie
per
specimen
fig
show
instrument
workflow
pcr
run
cycl
fluoresc
read
analyz
resultcal
algorithm
rca
determin
posit
neg
call
cartridg
includ
fullprocess
intern
control
titer
bacteriophag
dri
form
rehydr
upon
specimen
load
control
materi
verifi
step
analysi
process
qiastatdx
rp
analyz
perform
autom
result
analysi
target
valid
run
report
posit
neg
qualit
result
display
instrument
screen
print
intern
control
fail
softwar
automat
provid
result
target
test
posit
panel
target
result
invalid
within
softwar
report
display
amplif
curv
target
cycl
threshold
ct
endpoint
fluoresc
valu
provid
final
print
report
studi
conduct
investigationaluseonli
iuo
version
qiastatdx
rp
ident
final
fdaclearedceivdmark
version
compar
test
consist
filmarray
respiratori
panel
version
test
target
test
perform
sourc
laboratori
assay
detect
adenoviru
coronaviru
coronaviru
coronaviru
coronaviru
human
metapneumoviru
influenza
influenza
influenza
influenza
influenza
b
parainfluenza
viru
parainfluenza
viru
parainfluenza
viru
parainfluenza
viru
rhinovirusenteroviru
respiratori
syncyti
viru
bordetella
pertussi
chlamydophila
pneumonia
mycoplasma
pneumonia
qiastatdx
respiratori
panel
result
consid
true
posit
tp
true
neg
tn
agre
result
compar
method
discrep
analysi
ensu
result
discord
ie
falseposit
fp
falseneg
fn
result
discrep
analysi
panel
target
exclud
bordetella
pertussi
perform
use
nxtag
respiratori
pathogen
panel
luminex
magpix
instrument
one
clinic
studi
site
indiana
univers
school
medicin
b
pertussi
discord
analysi
verigen
respiratori
pathogen
flex
test
rp
flex
use
detect
differenti
follow
bordetella
speci
bordetella
parapertussisbronchiseptica
bordetella
holmesii
bordetella
pertussi
test
perform
one
clinic
studi
site
laboratori
allianc
central
new
york
note
perform
data
sensitivityposit
percent
agreement
ppa
specificityneg
percent
agreement
npa
present
work
consist
unresolv
data
present
packag
insert
fdaclear
test
discrep
investig
provid
use
recalcul
perform
data
workflow
analysi
oper
procedur
compar
determin
differ
number
step
requir
setup
total
specimen
set
analysi
method
time
requir
begin
setup
load
instrument
measur
addit
random
sampl
result
gener
specimen
run
qiastatdx
rp
analyz
averag
time
result
platform
calcul
binomi
twosid
confid
interv
ci
calcul
use
wilson
score
method
differ
median
ct
valu
determin
use
mood
median
test
total
specimen
prospect
retrospect
includ
data
analysi
arm
studi
collect
rang
geographicdemograph
popul
tabl
overal
specimen
includ
slightli
femal
male
subject
respect
specimen
variou
age
group
specimen
children
age
age
adult
age
adult
age
treatment
set
obtain
hospit
patient
visit
emerg
depart
admit
intens
care
unit
icu
obtain
subject
seen
outpati
set
specimen
locat
list
unknown
total
specimen
origin
enrol
arm
studi
prospect
frozen
fresh
retrospect
archiv
frozen
total
prospect
specimen
exclud
reason
relat
sampl
stabil
test
perform
fourteen
retrospect
sampl
withdrawn
target
interest
confirm
repeat
test
compar
assay
prospect
specimen
test
analyz
clinic
evalu
yield
valid
result
first
attempt
ie
first
load
cartridg
invalid
result
obtain
remain
specimen
fortytwo
specimen
invalid
due
cartridg
intern
control
failur
provid
result
posit
detect
target
detect
specimen
result
obtain
due
incomplet
run
one
specimen
abort
user
due
instrument
error
due
cartridgerel
error
seventytwo
initi
fail
result
invalid
specimen
yield
valid
result
singl
retest
use
new
cartridgespecimen
remain
specimen
fail
second
attempt
two
due
cartridg
failur
one
due
instrument
error
seven
due
intern
control
failur
intern
control
failur
detect
pathogen
report
four
specimen
thu
six
sampl
provid
valid
result
singl
retest
yield
success
rate
singl
retest
prospect
specimen
qiastatdx
rp
detect
least
one
analyt
specimen
test
yield
overal
posit
rate
tabl
highest
detect
rate
seen
young
children
year
age
follow
year
age
summari
prospect
perform
characterist
individu
qiastatdx
rp
target
present
tabl
ppa
npa
calcul
respect
compar
method
along
ci
qiastatdx
rp
demonstr
ppa
greater
three
analyt
flu
ppa
could
calcul
three
analyt
demonstr
ppa
cov
cov
cov
cov
addit
nine
analyt
demonstr
lower
bound
twosid
ci
due
observ
studi
overal
qiastatdx
rp
demonstr
npa
analyt
lower
bound
twosid
ci
qiastatdx
rp
detect
total
specimen
distinct
multipleorgan
detect
repres
prospect
sampl
doubl
infect
tripl
infect
quadrupl
infect
rate
multipl
detect
age
group
year
year
year
year
three
pathogen
preval
multipl
detect
rvev
rsv
adenoviru
ii
retrospect
specimen
perform
characterist
retrospect
specimen
present
tabl
qiastatdx
rp
detect
least
one
analyt
specimen
test
yield
overal
posit
rate
tabl
neg
sampl
compar
test
posit
pathogen
interest
retest
accru
freezethaw
cycl
test
qiastatdx
rp
smaller
archiv
sampl
set
ppa
target
lower
bound
ci
ppa
also
lower
prospect
group
due
fewer
sampl
test
valu
npa
target
sampl
preselect
preval
evalu
iii
compar
analysi
discrep
investig
total
analyz
qiastatdx
rp
pathogen
result
specimen
prospect
retrospect
overal
percent
agreement
qiastatdx
rp
compar
test
detect
pathogen
result
qiastatdx
rp
compar
method
posit
pathogen
detect
overal
ppa
respect
compar
method
data
median
ct
valu
posit
detect
qiastatdx
rp
present
supplement
materi
tabl
detect
result
qiastatdx
rp
compar
method
neg
analyt
overal
npa
respect
compar
method
viral
analyt
qiastatdx
rp
detect
total
viral
analyt
compar
use
compar
true
result
overal
ppa
npa
respect
viru
target
use
compar
true
result
overal
ppa
npa
respect
bacteri
target
use
compar
test
true
result
fp
detect
fn
detect
overal
addit
discrep
analysi
perform
fals
detect
fp
case
along
fn
case
support
evid
qiastatdx
rp
result
bring
adjud
overal
concord
posit
neg
result
respect
summari
discrep
investig
present
tabl
iv
workflow
time
result
review
procedur
show
step
set
pouch
load
instrument
differ
two
platform
specimen
pipet
directli
qiastatdx
fa
requir
addit
sampl
diluent
use
inject
vial
reagent
hydrat
sampl
prepar
addit
transfer
pipett
manipul
specimen
time
studi
setup
pouch
two
oper
specimen
load
took
averag
qiastatdx
rp
averag
time
result
pair
run
determin
instrument
min
qiastatdx
rp
min
common
viral
analyt
rvev
total
posit
detect
extens
divers
within
rhinovirus
mean
molecular
assay
includ
qiastatdx
rp
compar
assay
target
untransl
region
utr
region
highli
conserv
among
rhinovirus
enterovirus
caus
crossreact
assay
two
virus
make
differenti
difficult
rvev
also
target
show
highest
number
discord
result
discord
specimen
analyz
nxtag
respiratori
pathogen
panel
anoth
fdaclear
multiplex
target
therefor
definit
resolut
type
viru
rhinoviru
versu
enteroviru
made
fp
fn
sampl
adenovirus
qiastatdx
rp
design
detect
genogroup
b
c
e
type
commonli
associ
respiratori
infect
also
detect
degre
genotyp
f
g
evidenc
contriv
test
type
strain
also
design
detect
genotyp
b
c
e
test
use
hexon
gene
target
differ
perform
two
test
present
studi
may
relat
specif
primer
probe
sequenc
differ
level
sensit
specif
assay
mani
differ
serotyp
adenoviru
prior
studi
demonstr
signific
number
adenovirus
upperrespiratorytract
sampl
may
genogroup
f
could
miss
test
design
broad
coverag
adenovirus
recent
data
suggest
broaden
inclus
target
nonrespiratori
type
improv
clinic
assay
perform
qiastatdx
rp
assay
distinct
target
detect
cov
three
four
target
tabl
ppa
lowest
valu
analyt
prospect
analysi
contrast
retrospect
cov
specimen
show
better
posit
agreement
target
tabl
unclear
differ
perform
two
arm
studi
rel
small
number
posit
detect
gener
addit
fp
sampl
significantli
higher
ct
valu
tp
sampl
see
tabl
supplement
materi
suggest
fp
relat
low
level
viru
level
viru
fn
specimen
estim
semiquantit
valu
ct
provid
among
virus
detect
multiplex
panel
substanti
evid
rapid
molecular
diagnosi
influenza
viru
infect
impact
patient
outcom
adult
pediatr
popul
qiastatdx
rp
total
target
detect
flu
paninfluenza
target
specif
target
subtyp
influenza
influenza
influenza
influenza
aposit
detect
total
addit
subtypespecif
detect
specif
detect
detect
season
three
influenza
posit
associ
specif
detect
could
due
viru
level
limit
detect
typespecif
assay
howev
indic
detect
novel
influenza
type
consid
seen
clinic
use
flu
b
viru
singl
target
design
detect
two
sublineag
viru
victoria
lineag
yamagata
lineag
fn
result
qiastatdx
rp
may
reflect
differ
sensit
relat
viral
strain
compar
provid
semiquantit
valu
difficult
determin
rel
level
viru
qiastatdx
fn
howev
fn
ct
valu
suggest
signific
amount
viru
present
rel
small
number
bacteri
detect
found
prospect
cohort
seen
studi
multiplex
test
common
bacteri
target
pneumonia
detect
detect
howev
note
use
np
specimen
detect
pneumonia
may
suboptim
particularli
diagnos
lowerrespiratorytract
infect
b
pertussi
discrep
qiastatdx
rp
compar
method
unexpect
qiastatdx
rp
target
multicopi
insert
sequenc
present
sever
bordetella
speci
b
pertussi
b
holmesii
b
bronchiseptica
wherea
compar
target
singlecopi
promot
region
pertussi
toxin
gene
design
specif
detect
b
pertussi
use
singlecopi
toxin
gene
target
shown
less
sensit
use
assay
use
discord
analysi
call
individu
bordetella
speci
b
pertussi
b
parapertussi
b
holmesii
b
pertussi
target
also
toxin
promot
region
thu
would
singlecopi
gene
total
qiastatdx
rp
fp
result
found
b
pertussi
arm
studi
tabl
five
sampl
avail
analysi
one
confirm
use
discord
test
ct
valu
examin
ct
valu
detect
clinic
trial
discord
detect
significantli
higher
median
ct
valu
concord
posit
detect
tp
median
ct
fp
median
ct
p
tabl
thu
fp
may
miss
compar
discord
analysi
assay
base
lower
sensit
singlecopi
gene
target
multiplex
respiratori
panel
qiastatdx
rp
allow
detect
multipl
pathogen
repres
coinfect
rate
codetect
highest
pediatr
patient
year
age
common
analyt
codetect
rvev
rsv
adenoviru
similar
find
report
multiplex
respiratori
panel
data
need
impact
codetect
outcom
howev
may
use
infect
control
purpos
allow
better
cohort
isol
infect
patient
qiastatdx
rp
workflow
simpl
footprint
instrument
small
measur
cm
width
cm
height
cm
depth
one
oper
modul
plu
one
analyt
modul
width
height
depth
fig
compar
qiastatdx
rp
involv
one
step
pipett
specimen
cartridg
load
buffer
ad
manipul
requir
lessen
manipul
may
help
reduc
contamin
run
time
similar
last
averag
min
qiastatdx
rp
respect
platform
allow
test
one
pouch
time
per
modul
term
reliabl
initi
rate
invalid
result
first
test
prospect
sampl
second
test
invalid
rate
compar
multiplex
platform
current
avail
signific
benefit
system
allow
user
obtain
ct
valu
detect
pathogen
intern
control
compar
assay
allow
user
see
ct
valu
valu
truli
quantit
allow
semiquantit
assess
target
amount
use
troubleshoot
qualiti
control
measur
limit
studi
prospect
arm
specimen
test
fresh
frozen
prior
test
howev
data
indic
frozen
storag
significantli
affect
perform
studi
period
bridg
month
includ
two
respiratori
season
howev
variat
circul
strain
particularli
influenza
virus
may
limit
preval
analyt
low
prospect
cohort
frozen
retrospect
sampl
use
increas
number
posit
detect
state
freezethaw
appear
affect
perform
term
preval
howev
retrospect
sampl
test
test
compar
assay
freezethaw
cycl
remov
confound
overal
percentag
discrep
result
versu
compar
method
low
summari
qiastatdx
rp
demonstr
good
compar
perform
larg
multicent
clinic
trial
repres
new
altern
multiplex
respiratori
test
robust
accur
assay
rapid
comprehens
test
respiratori
pathogen
nasopharyng
swab
specimen
